Go to deals
Healthcare

Igyxos S.A. has completed a Series A fundraising

Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.

Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.

Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Jean-Paul  Ortelli

Jean-Paul Ortelli

Senior Advisor

Paris, France
Oaklins France
 Leïla  Djebli

Leïla Djebli

Associate Director

Paris, France
Oaklins France

Related deals

GeneTech Inc. has been acquired by Eurofins
Healthcare

GeneTech Inc. has been acquired by Eurofins

Noritsu Koki Ltd. has sold GeneTech Inc. to Eurofins Clinical Testing Holding Lux S.à r.l.

Learn more
MediCa group has been acquired by Repharm
Healthcare

MediCa group has been acquired by Repharm

CGP Management has sold MediCa group, the largest private provider of healthcare services in Lithuania, to Repharm.

Learn more
The MOLE Clinic Limited has been acquired by Sk:n (backed by TriSpan)
Private Equity | Healthcare

The MOLE Clinic Limited has been acquired by Sk:n (backed by TriSpan)

The shareholders of The MOLE Clinic Limited have sold the company to Sk:n.

Learn more